- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02309008
A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects
April 20, 2016 updated by: Amorepacific Corporation
A Randomized, Double-blind, Placebo-controlled Multiple Dosing Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream After Transdermal Administration in Healthy Volunteers
The purpose of this study is to investigate the safety/tolerability and pharmacokinetics of PAC-14028 cream after transdermal administration in healthy male volunteers.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital Clinical Trials Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Healthy men aged 19 to 65 years at the time of screening
Whose weight is 50 kg or more, but less than 90 kg, and whose body mass index (BMI) is 18.0 kg/m^2 or more but less than 27 kg/m^2
- BMI (kg/m^2) = weight(kg) /{height(m)}^2
- Who doesn't have skin disease, skin damage (including tatoos or scars), or excessive hair in application area which can affect drug absorption
- Who voluntarily decides study participation after receiving detailed explanation about the study and fully understanding it and who provides written consent for compliance with study requirement including proper contraception
Exclusion Criteria:
- Who has clinically significant medical history or diseases involving liver, kidney, neurological system, respiratory system, endocrine system, urinary system, cardiovascular system,skin, psychical disorders or blood tumor
- Who has a history of hypersensitivity or allergies to any drug (aspirin, antibiotics, etc)
- Who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks before study drug administration, or who has taken any over-the-counter (OTC) drugs or vitamins within 1 week before the study drug initiation (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
- Who has drug abuse history or positive result at urine screening tests (cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine)
- Who has smoked within 3 months before study drug administration (Smoker who has stopped smoking for more than 3 months before study drug administration is eligible to participate)
- Who has confirmed positive at serological tests (HBs antigen, HCV antibody and HIV antibody)
- Who consistently consumes alcohol
- Who has participated in other clinical study within 8 weeks before study drug administration (however, the last dosing day is considered as the end of clinical study.)
- Who has had bleeding or blood collection and donation over 400 mL within 8 weeks before study drug administration
- Who donated whole blood within 2 months before study drug administration, who donated via plasmapheresis/plateletpheresis within 1 month before study drug administration, or who received a blood transfusion within 1 month before study drug administration
Whose vital sign measured at sitting position after resting at least 3 minutes is as following
- Low blood pressure (Systolic pressure: less than 90 mmHg, Diastolic pressure: less than 60 mmHg)
- High blood pressure (Systolic pressure: higher than 150 mmHg, Diastolic pressure: higher than 100 mmHg)
- Who is determined ineligible for study participation by investigators for any reason including clinical lab test and ECG results.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
vehicle cream, dermal administration, multiple dosing
|
Participants will receive vehicle cream applied topically once a day for 9 days
Other Names:
|
Experimental: drug
PAC-14028 cream, dermal administration, multiple dosing, dose escalation
|
Participants will receive PAC-14028 cream applied topically once a day for 9 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety/Tolerability (adverse events, abnormal vital signs, ECG test, clinical lab tests, Numerical pain recording scale)
Time Frame: Day 1~9, at specified time for each tests
|
AE incidence pattern, abnormal findings in vital sign, ECG test, and clinical lab tests, Numerical pain recording scale
|
Day 1~9, at specified time for each tests
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (Concentration of PAC-14028 in Blood; Cmax, AUC)
Time Frame: Day 1: 0 ~ 16h ; Day 2~8: 0h ; Day 9: 0 ~ 96h
|
Concentration of PAC-14028 in Blood; Cmax, AUC
|
Day 1: 0 ~ 16h ; Day 2~8: 0h ; Day 9: 0 ~ 96h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2014
Primary Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
December 3, 2014
First Submitted That Met QC Criteria
December 4, 2014
First Posted (Estimate)
December 5, 2014
Study Record Updates
Last Update Posted (Estimate)
April 22, 2016
Last Update Submitted That Met QC Criteria
April 20, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AP-TRPV1-PI-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Vehicle
-
Haus BioceuticalsCompletedEczema | Atopic DermatitisIndia
-
PfizerCompleted
-
LEO PharmaCompleted
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
Johns Hopkins Bloomberg School of Public HealthCompletedObesity | Childhood Obesity | Dietary Habits | Water; Lack of | Feeding Behavior | Mother-Child RelationsUnited States
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
University of British ColumbiaUnknownCicatrix | Scar | Keloid | Hypertrophic Scar | Skin Graft Scar | Skin Graft Complications | Donor Site ComplicationCanada
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States